ETON vs. TVTX, VIR, GPCR, XNCR, SDGR, ARDX, NRIX, KNSA, OCUL, and RCUS
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Travere Therapeutics (TVTX), Vir Biotechnology (VIR), Structure Therapeutics (GPCR), Xencor (XNCR), Schrödinger (SDGR), Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs.
Travere Therapeutics (NASDAQ:TVTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Travere Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 29.48%. Eton Pharmaceuticals has a consensus target price of $18.67, suggesting a potential upside of 27.20%. Given Travere Therapeutics' higher possible upside, equities research analysts plainly believe Travere Therapeutics is more favorable than Eton Pharmaceuticals.
Eton Pharmaceuticals has lower revenue, but higher earnings than Travere Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 15 mentions for Eton Pharmaceuticals and 12 mentions for Travere Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.79 beat Travere Therapeutics' score of 0.74 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 4.1% of Travere Therapeutics shares are owned by company insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eton Pharmaceuticals received 15 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 64.83% of users gave Eton Pharmaceuticals an outperform vote while only 57.66% of users gave Travere Therapeutics an outperform vote.
Travere Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Eton Pharmaceuticals has a net margin of -15.81% compared to Travere Therapeutics' net margin of -172.75%. Eton Pharmaceuticals' return on equity of -36.29% beat Travere Therapeutics' return on equity.
Summary
Eton Pharmaceuticals beats Travere Therapeutics on 15 of the 19 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 1/17/2025 by MarketBeat.com Staff
Free ETON Stock Alerts